Wird geladen...
Profile of olaparib in the treatment of advanced ovarian cancer
Olaparib is a poly(ADP-ribose) polymerase inhibitor that received accelerated approval from the US Food and Drug Administration as monotherapy for patients with germline BRCA mutations and ovarian cancer treated with three or more prior lines of chemotherapy. This article summarizes the mechanism of...
Gespeichert in:
| Veröffentlicht in: | Int J Womens Health |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Dove Medical Press
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4847603/ https://ncbi.nlm.nih.gov/pubmed/27186080 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJWH.S55906 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|